Our combination of NIR-PIT using the HER2 Affibody-IR700Dye conjugate and the trastuzumab-IR700Dye conjugate caused selective cell death of HER2-positive cancer cells and successfully maintained the lowest cell viability even 5 days after the NIR-PIT (Figure 5 and Figure 6 and Supplementary Figure S3). This evidence concerns the gene ERBB2 and cancer.